Wei Huang1, Robert J Goldberg2, Frederick A Anderson3, Catarina I Kiefe2, Frederick A Spencer4. 1. Center for Outcomes Research, Department of Surgery, University of Massachusetts Medical School, Worcester. Electronic address: wei.Huang@umassmed.edu. 2. Department of Quantitative Health Science, University of Massachusetts Medical School, Worcester. 3. Center for Outcomes Research, Department of Surgery, University of Massachusetts Medical School, Worcester. 4. Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
Abstract
BACKGROUND: The clinical epidemiology of venous thromboembolism has changed recently because of advances in identification, prophylaxis, and treatment. We sought to describe secular trends in the occurrence of venous thromboembolism among residents of the Worcester, Massachusetts, metropolitan statistical area. METHODS: Population-based methods were used to monitor trends in event rates of first-time or recurrent venous thromboembolism in 5025 Worcester, Massachusetts, metropolitan statistical area residents who were diagnosed with acute pulmonary embolism or lower-extremity deep vein thrombosis during 9 annual periods between 1985 and 2009. Medical records were reviewed by abstractors and validated by clinicians. RESULTS: Age- and sex-adjusted annual event rates for first-time venous thromboembolism increased from 73 (95% confidence interval [CI], 64-82) per 100,000 in 1985/1986 to 133 (CI, 122-143) in 2009, primarily because of an increase in pulmonary embolism. The rate of recurrent venous thromboembolism decreased from 39 (CI, 32-45) in 1985/1986 to 19 (CI, 15-23) in 2003, and then increased to 35 (CI, 29-40) in 2009. There was an increasing trend in using noninvasive diagnostic testing, with approximately half of tests being invasive in 1985/1986 and almost all noninvasive by 2009. CONCLUSIONS: Despite advances in identification, prophylaxis, and treatment between 1985 and 2009, the annual event rate of venous thromboembolism has increased and remains high. Although these increases partially may be due to increased sensitivity of diagnostic methods, especially for pulmonary embolism, they also may imply that current prevention and treatment strategies are less than optimal.
BACKGROUND: The clinical epidemiology of venous thromboembolism has changed recently because of advances in identification, prophylaxis, and treatment. We sought to describe secular trends in the occurrence of venous thromboembolism among residents of the Worcester, Massachusetts, metropolitan statistical area. METHODS: Population-based methods were used to monitor trends in event rates of first-time or recurrent venous thromboembolism in 5025 Worcester, Massachusetts, metropolitan statistical area residents who were diagnosed with acute pulmonary embolism or lower-extremity deep vein thrombosis during 9 annual periods between 1985 and 2009. Medical records were reviewed by abstractors and validated by clinicians. RESULTS: Age- and sex-adjusted annual event rates for first-time venous thromboembolism increased from 73 (95% confidence interval [CI], 64-82) per 100,000 in 1985/1986 to 133 (CI, 122-143) in 2009, primarily because of an increase in pulmonary embolism. The rate of recurrent venous thromboembolism decreased from 39 (CI, 32-45) in 1985/1986 to 19 (CI, 15-23) in 2003, and then increased to 35 (CI, 29-40) in 2009. There was an increasing trend in using noninvasive diagnostic testing, with approximately half of tests being invasive in 1985/1986 and almost all noninvasive by 2009. CONCLUSIONS: Despite advances in identification, prophylaxis, and treatment between 1985 and 2009, the annual event rate of venous thromboembolism has increased and remains high. Although these increases partially may be due to increased sensitivity of diagnostic methods, especially for pulmonary embolism, they also may imply that current prevention and treatment strategies are less than optimal.
Authors: Frederick A Spencer; Cathy Emery; Darleen Lessard; Frederick Anderson; Sri Emani; Jayashri Aragam; Richard C Becker; Robert J Goldberg Journal: J Gen Intern Med Date: 2006-07 Impact factor: 5.128
Authors: C Kearon; M Gent; J Hirsh; J Weitz; M J Kovacs; D R Anderson; A G Turpie; D Green; J S Ginsberg; P Wells; B MacKinnon; J A Julian Journal: N Engl J Med Date: 1999-03-25 Impact factor: 91.245
Authors: P Prandoni; A W Lensing; H R Büller; M Carta; A Cogo; M Vigo; D Casara; A Ruol; J W ten Cate Journal: Lancet Date: 1992-02-22 Impact factor: 79.321
Authors: Karl Y Bilimoria; Jeanette Chung; Mila H Ju; Elliott R Haut; David J Bentrem; Clifford Y Ko; David W Baker Journal: JAMA Date: 2013-10-09 Impact factor: 56.272
Authors: M Levine; M Gent; J Hirsh; J Leclerc; D Anderson; J Weitz; J Ginsberg; A G Turpie; C Demers; M Kovacs Journal: N Engl J Med Date: 1996-03-14 Impact factor: 91.245
Authors: John A Heit; Aneel Ashrani; Daniel J Crusan; Robert D McBane; Tanya M Petterson; Kent R Bailey Journal: Thromb Haemost Date: 2016-12-15 Impact factor: 5.249
Authors: Majed S Al Yami; Hisham A Badreldin; Abdelhameed H Mohammed; Ahmed M Elmubark; Mohammed Y Alzahrani; Abdulmajeed M Alshehri Journal: J Thromb Thrombolysis Date: 2018-08 Impact factor: 2.300
Authors: John Fanikos; Leo F Buckley; Ahmed Aldemerdash; Kimberly J Terry; Gregory Piazza; Jean M Connors; Samuel Z Goldhaber Journal: J Thromb Thrombolysis Date: 2015-04 Impact factor: 2.300